@article{100642,
  keywords = {Onchocerciasis-associated epilepsy, Modelling, Ivermectin, Treatment, Prevalence, Incidence.},
  author = {Stapley J and Hamley J and Walker M and Dixon M and Colebunders R and Basáñez M},
  title = {Modelling onchocerciasis-associated epilepsy and the impact of ivermectin treatment on its prevalence and incidence.},
  abstract = {<p>Retrospective cohort studies in Cameroon found an association between Onchocerca volvulus microfilarial load in childhood (measured in 1991-1993) and risk of developing epilepsy later in life (measured in 2017). We parameterised and integrated this relationship (across children aged 3-15 years) into the previously published, stochastic transmission model, EPIONCHO-IBM, for Simulium damnosum sensu lato-transmitted onchocerciasis. We simulated 19 years (1998-2017) of annual ivermectin mass drug administration (MDA) reflecting coverage in the study area, and modelled epilepsy prevalence and incidence. Scenario-based simulations of 25 years of (annual and biannual) MDA in hyper- and holoendemic settings, with 65% and 80% therapeutic coverage, were also conducted. EPIONCHO-IBM predicted 7.6% epilepsy prevalence (compared to 8.2% in the Cameroon study) and incidence of 317 cases/100,000 person-years (compared to 350). In hyperendemic areas, 25 years of biannual MDA (80% coverage) eliminated onchocerciasis-associated epilepsy (OAE) and protected untreated under-fives from its development. Strengthening onchocerciasis programmes, implementing alternative strategies, and evaluating treatment for under-fives and school-age children are crucial to prevent OAE in highly-endemic settings.</p>},
  year = {2024},
  journal = {Nature communications},
  volume = {15},
  pages = {1-11},
  month = {07/2024},
  issn = {2041-1723},
  url = {https://www.nature.com/articles/s41467-024-50582-9.pdf},
  doi = {10.1038/s41467-024-50582-9},
  language = {ENG},
}